Valneva : Large & Midcap Event

Advancing Vaccines for Better Lives

Valneva Presentation

Large & Midcap Event

October 2020

Valneva - Large & Midcap Event

October 2020

1

Disclaimer

This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The Valneva shares may not be offered or sold in the USA. The offer and sale of the Valneva shares has not been and will not be registered under the 1933 US Securities Act, as amended.

Valneva is a European company. Information distributed is subject to European disclosure requirements that are different from those of the United States. Financial statements and information may be prepared according to accounting standards which may not be comparable to those used generally by companies in the United States.

This presentation includes only summary information and does not purport to be comprehensive. Any information in this presentation is purely indicative and subject to modification at any time. Valneva does not warrant the completeness, accuracy or correctness of the information or opinions contained in this presentation. None of Valneva, or any of their affiliates, directors, officers, advisors and employees shall bear any liability for any loss arising from any use of this presentation.

Certain information and statements included in this presentation are not historical facts but are forward-looking statements. The forward-looking statements (a) are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Valneva operates, and involve known and unknown risk, uncertainties and other factors, which may cause actual results, performance or achievements to be materially different from those expressed or implied by these forward-looking statements, (b) speak only as of the date this presentation is released, and (c) are for illustrative purposes only. Investors are cautioned that forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Valneva.

Valneva - Large & Midcap Event

October 2020

2

As a specialty vaccine company, Valneva currently focuses its development activities on three unique vaccine candidates:

Lyme disease		COVID-19		Chikungunya

Valneva - Large & Midcap Event

October 2020

3

Valneva's Pipeline

Product	Pre-clinical Phase 1	Phase 2	Phase 3	Partner	PRV*
Candidate					Eligible
VLA1553				proprietary	
Chikungunya

VLA15		Pfizer
Lyme disease
VLA2001		proprietary
COVID-19

*PRV = U.S. Priority Review Voucher: https://priorityreviewvoucher.org/

Valneva - Large & Midcap Event

October 2020

4